• 00:01 🦠 Vitamin D supplementation reduces the incidence of COVID-19.

  • Vitamin D supplementation has a protective effect against COVID-19 in randomized controlled trials.
  • Odds ratio of 0.43 indicates a 60% protective effect.
  • Healthcare workers experienced an 80% reduction in risk with vitamin D supplementation.

• 02:47 📊 Meta-analysis confirms significant association between vitamin D and COVID-19 protection.

  • Meta-analysis concludes a definitive and significant link between vitamin D and reduced COVID-19 incidence.
  • Study titled "Vitamin D Supplementation and the Risk for COVID-19 Infection: A Systematic Review and Meta-analysis" published in February 2024.
  • Consensus on the protective role of vitamin D in both COVID-19 incidence and ICU admissions.

• 03:02 📚 Vitamin D's crucial roles in health and immunity.

  • Vitamin D plays crucial roles in bone health, muscle function, and immune response.
  • Optimizing vitamin D levels may protect against a range of cancers.
  • Strong scientific evidence supports the importance of vitamin D in immune system modulation.

• 04:25 🧪 Understanding the role of vitamin D in immune response.

  • Systematic reviews and meta-analysis highlight vitamin D's impact on the immune response to viruses.
  • Vitamin D supplementation shows a protective role in COVID-19 incidence among a large population.
  • Further research is needed to determine vitamin D's impact on mortality rates.

• 06:28 💡 Mechanisms of vitamin D action in the body.

  • Vitamin D mediates its effects through vitamin D receptors (VDRs) in nucleated cells.
  • VDR activation by vitamin D regulates gene expression crucial for immunity and metabolism.
  • Approximately 3% of the human genome is under the control of activated vitamin D, emphasizing its broad impact on health.

• 08:01 🔬 Vitamin D's role in immune function and disease prevention.

  • Vitamin D contributes to the synthesis of immune proteins and enhances phagocytic activity.
  • Modulates the immune system response by regulating inflammatory cascades, reducing the risk of cytokine storms.
  • Optimizing vitamin D levels may help mitigate pathological reactions to infections.

• 09:34 💊 Immediate benefits of activated vitamin D (calcidiol) supplementation.

  • Activated vitamin D (calcidiol) offers immediate benefits compared to standard vitamin D supplementation.
  • Calcidiol activates within a couple of hours, potentially aiding in combating acute infections.
  • Consideration of calcidiol supplementation for individuals with low vitamin D levels during acute infections is suggested.

• 11:41 ✅ Advocating for vitamin D supplementation in healthcare.

  • Research supports the efficacy of vitamin D in reducing COVID-19 incidence and severity.
  • Urgent consideration for vitamin D supplementation in acute infection cases is recommended.
  • The accessibility and affordability of vitamin D make it a viable option for public health intervention.

You need Magnesium w/ Vitamin D....and vitamin K?

Vitamin D3 supplementation in the range of 4000 to 10,000 units (100 to 250 µg) needed to generate an optimal 40–60 ng/mL (100 to 150 nmol/L)

has been shown to be completely safe when combined with approximately 200 µg vitamin K2

Background: COVID-19 is a major pandemic that has killed more than 196,000 people. The COVID-19 disease course is strikingly divergent. Approximately 80-85% of patients experience mild or no symptoms, while the remainder develop severe disease. The mechanisms underlying these divergent outcomes are unclear. Emerging health disparities data regarding African American and homeless populations suggest that vitamin D insufficiency (VDI) may be an underlying driver of COVID-19 severity. To better define the VDI-COVID-19 link, we determined the prevalence of VDI among our COVID-19 intensive care unit (ICU) patients. Methods: In an Institutional Review Board approved study performed at a single, tertiary care academic medical center, the medical records of COVID-19 patients were retrospectively reviewed. Subjects were included for whom serum 25-hydroxycholecalcifoerol (25OHD) levels were determined. COVID-19-relevant data were compiled and analyzed. We determined the frequency of VDI among COVID-19 patients to evaluate the likelihood of a VDI-COVID-19 relationship. Results: Twenty COVID-19 patients with serum 25OHD levels were identified; 65.0% required ICU admission.The VDI prevalence in ICU patients was 84.6%, vs. 57.1% in floor patients. Strikingly, 100% of ICU patients less than 75 years old had VDI. Coagulopathy was present in 62.5% of ICU COVID-19 patients, and 92.3% were lymphocytopenic. Conclusions: VDI is highly prevalent in severe COVID-19 patients. VDI and severe COVID-19 share numerous associations including hypertension, obesity, male sex, advanced age, concentration in northern climates, coagulopathy, and immune dysfunction. Thus, we suggest that prospective, randomized controlled studies of VDI in COVID-19 patients are warranted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the following sources: 1) Louisiana State University Health Sciences Center; 2) 1R01HL118557-01A1, NIHLBI, NIH; 3) ASH Bridge Funding; 4) Texas A&M University System; 5) National Institutes of Health grant AI40165.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The authors confirm that the data supporting the findings of this study are available within the article.